Rapid Review of Rozanolixizumab (Rystiggo) for gMG Completed by NCPE (ncpe.ie)

• NCPE completed rapid review for rozanolixizumab (Rystiggo) for gMG.
• Rapid review commissioned 13 May 2026, completed 28 May 2026.
• Outcome: full HTA recommended to assess clinical and cost effectiveness.
• Indication: add-on therapy for anti-AChR or anti-MuSK positive gMG.

"The National Centre for Pharmacoeconomics (NCPE) published a rapid health technology assessment (HTA) for rozanolixizumab (Rystiggo), indicated as add-on therapy for anti-AChR or anti-MuSK antibody positive generalized myasthenia gravis (gMG) in adults. The rapid review was commissioned on 13 May 2026 and completed on 28 May 2026. The outcome recommends a full HTA to assess clinical effectiveness and cost effectiveness compared to current standard of care. This is part of the NCPE's drug reimbursement process."